Detection of tissue factor-positive extracellular vesicles using the ExoView R100 system.Background
 We hypthesised that ExoView can allow for direct measurement of TF+ EV in plasma, antigenically.


 We utilized the anti-TF monoclonal antibody 5G9 to capture TF EV onto specialized ExoView chips.  We compared ExoView results with an EV TF activity assay.


 BxPC-3-derived TF+ EVs were identified with ExoView using 5G9 capture with IIID8-AF647 detection.  Trauma patient samples had higher levels of EV TF activity than healthy controls, but activity did not correlate with TF measurements made by ExoView (R2 = 0.15).  Samples from patients with ovarian cancer have higher levels of EV TF activity than those from healthy controls, but activity did not correlate with TF measurement by ExoView (R2 = 0.0063).


 TF+ EV measurement is possible in plasma, but the threshold and potential clinical applicability of ExoView R100, in this context, remain to be established.
ExoView
Detection of tissue factor-positive extracellular vesicles using the ExoView R100 system.Background

ExoView R100 system